Concert Pharmaceuticals, Inc. (CNCE) Posts Mixed Q1 Results

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) reported Q1 EPS of ($0.76), $0.27 worse than the analyst estimate of ($0.49). Revenue for the quarter came in at $1.61 million versus the consensus estimate of $440 thousand.

For earnings history and earnings-related data on Concert Pharmaceuticals, Inc. (CNCE) click here.

You May Also Be Interested In

• Nomura/Instinet Upgrades Genting Singapore (GENS:SP) (GIGNY) to Neutral
• Companhia de Saneamento Básico do Estado de São Paulo - SABESP (SBS) Tops Q2 EPS by 24c
• Eledon Pharmaceuticals, Inc. (ELDN) Misses Q2 EPS by 12c